Seroprevalence of SARS-CoV-2 specific Immunoglobin G antibodies in rural population of Western Maharashtra, India

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, responsible for the coronavirus disease 2019 (COVID-19) pandemic, has been a major public health concern requiring continuous efforts for understanding its epidemiology. Patients infected with SARS-CoV-2 have a wide range of clinical features ranging from asymptomatic infection to mild or severe illness with fatal outcomes or recovery. Population-based seroepidemiological studies are an effective method for measuring the rapid spread of SARS-CoV-2 and monitoring the pandemic’s progress. Methods We conducted repeated cross-sectional community-based sentinel surveillance between January and June 2021 in the rural parts of the Pune district of Maharashtra, India to assess the seroprevalence against SARS-CoV-2 in three age categories. We selected 30 clusters for each round using a proportional population sampling method and 30 individuals in each of the three age groups (1-17 years, 18-49 years, and ≥50 years). We took blood samples from consenting study participants to check for the presence of Immunoglobulin G (IgG) antibodies against SARS-CoV-2 in all five rounds. Results We included 14 274 individuals across five rounds; 29% were from the 1-17, 39% from the 18-49, and 32% from the ≥50-year-old group. Overall seroprevalence combining all rounds was 45%. There was an increase in seropositivity in rounds four (51.15%) and five (58.32%) contributed mostly by adults. We found that about 72% of elderly individuals ≥50 years in round five were seropositive. The factors strongly associated with the seropositivity were being in contact with suspected or confirmed cases of COVID-19 (odds ratio (OR) = 7.15; 95% confidence interval (CI) = 4.2-12.14), receiving at least one dose of COVID-19 vaccine (OR = 3.13 (95% CI = 0.70-14.07), being aged ≥50 years (OR = 1.97; 95% CI = 1.81-2.15), and being in an occupation belonging to a high-risk category (OR = 1.92; 95% CI = 1.65-2.26). Among 135 hospitalizations reported due to COVID-19-like illness, 91 (67%) were in the elderly age group of ≥50 and 33 (24%) were in the 18-49-year-old age group. Conclusions Seroprevalence of SARS-CoV-2 was high in the last two rounds (April to June 2021) which coincide with the second wave of the pandemic (Delta variant B.1.617.2) in India. Overall, one in three children and one in two adults had antibodies for SARS-CoV-2. The suspected or confirmed case of COVID-19 emerged as the significant factor strongly associated with the seropositivity followed by COVID-19 vaccination.

[1]  N. Sharma,et al.  The seroprevalence of severe acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based seroepidemiological study. , 2021, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[2]  Jitendra Narayan,et al.  Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India , 2021, Travel Medicine and Infectious Disease.

[3]  L. D. de Witte,et al.  High seroprevalence of COVID-19 infection in a large slum in South India; what does it tell us about managing a pandemic and beyond? , 2021, Epidemiology and Infection.

[4]  Sarang V Dhatrak,et al.  SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey , 2021, The Lancet Global Health.

[5]  Bhavin Solanki,et al.  Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study , 2021, BMJ Open.

[6]  Md. Zakiul Hassan,et al.  Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis , 2020, Vaccine.

[7]  M. Arunachalam,et al.  National Guidelines for Ethics Committees Reviewing Biomedical & Health Research during COVID-19 Pandemic: An analysis. , 2020, Indian journal of medical ethics.

[8]  G. Kang,et al.  Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India , 2020, The Lancet Global Health.

[9]  M. Venkataswamy,et al.  Descriptive epidemiology of SARS-CoV-2 infection in Karnataka state, South India: Transmission dynamics of symptomatic vs. asymptomatic infections , 2020, EClinicalMedicine.

[10]  D. Buonsenso,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in children with household exposition to adults with COVID-19: preliminary findings , 2020, medRxiv.

[11]  G. Corbi,et al.  COVID-19 and the elderly: insights into pathogenesis and clinical decision-making , 2020, Aging Clinical and Experimental Research.

[12]  A. Flahault,et al.  Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study , 2020, The Lancet.

[13]  Eric J Topol,et al.  Prevalence of Asymptomatic SARS-CoV-2 Infection , 2020, Annals of Internal Medicine.

[14]  R. Pandey,et al.  National sero-surveillance to monitor the trend of SARS-CoV-2 infection transmission in India: Protocol for community-based surveillance , 2020, The Indian journal of medical research.

[15]  P. Santhosh,et al.  First confirmed case of COVID-19 infection in India: A case report , 2020, The Indian journal of medical research.

[16]  D. Larremore,et al.  Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys , 2020, medRxiv.

[17]  M. Day Covid-19: four fifths of cases are asymptomatic, China figures indicate , 2020, BMJ.

[18]  Malik Peiris,et al.  Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  W. Ko,et al.  Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths , 2020, Journal of Microbiology, Immunology and Infection.

[20]  M. Lipsitch,et al.  Defining the Epidemiology of Covid-19 - Studies Needed. , 2020, The New England journal of medicine.

[21]  P. K. Anand,et al.  Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020 , 2020, The Indian journal of medical research.

[22]  K. Dierickx,et al.  Benefit sharing in the revised Indian National Ethical Guidelines for Biomedical and Health Research Involving Human Participants. , 2018, Indian journal of medical ethics.